MarketPeel
Insider Trading Intelligence
DD

David Dieter

COLL
EVP & GENERAL COUNSEL · COLLEGIUM PHARMACEUTICAL, INC · CIK 0002061438
FILING MIX · LIFETIME43%/57%
BUYS
3
SELLS
4
TOTAL VALUE
$1.16M
COMPANIES
1
ACTIVE SINCE
Mar 2025
HOLDINGS NOW
77,071
AVG SELL PX
$36.52
TRADE KIND
SHOWING 7 / 7
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
2 backtested trades · 8 horizons · 6 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by David Dieter, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d2+100.00%-4.44%-1.03%-3.41%-3.41%
14d2+100.00%-5.63%-2.15%-3.47%-3.47%
30d2+100.00%-5.71%+3.52%-9.23%-9.23%
60d2+0.00%+0.93%+10.49%-9.56%-9.56%
90d2+100.00%-5.39%+11.42%-16.81%-16.81%
180d2(2 pending)
1y2(2 pending)
2y2(2 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
COLL · 77,071 shares · as of Mar 18, 2026
025,01350,02675,039100,0522026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2025
2025
2025
2025
2026
FLOW · 3 buys / 4 sellsCOVERAGE · 5 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
COLL
COLLEGIUM PHARMACEUTICAL, INC
SALE10b5-1
10b5-1 plan
13,976$34.92$488.1K77,071Mar 18, 2026Mar 20, 2026View →
COLL
COLLEGIUM PHARMACEUTICAL, INC
SALE
EVP & General Counsel
8,840$35.72$315.8K68,231Mar 17, 2026Apr 3, 2026View →
COLL
COLLEGIUM PHARMACEUTICAL, INC
SALE10b5-1
10b5-1 plan
6,224$36.65$228.1K91,047Mar 9, 2026Mar 11, 2026View →
COLL
COLLEGIUM PHARMACEUTICAL, INC
PURCHASEGRANT
Stock grant
9,005100,052Feb 10, 2026Feb 12, 2026View →
COLL
COLLEGIUM PHARMACEUTICAL, INC
PURCHASEGRANT
Stock grant
22,19491,047Feb 10, 2026Feb 12, 2026View →
COLL
COLLEGIUM PHARMACEUTICAL, INC
SALE
EVP & General Counsel
2,781$46.75$130.0K97,271Feb 10, 2026Feb 12, 2026View →
COLL
COLLEGIUM PHARMACEUTICAL, INC
PURCHASEGRANT
Stock grant
68,44968,449Mar 17, 2025Mar 19, 2025View →
Other insiders · COLL
Loading peer insiders…
About this filer
CIK 0002061438
ROLE
EVP & General Counsel
PRIMARY
COLL
COMPANIES
1
ACTIVE SINCE
Mar 2025
MARKETPEEL · /INSIDER/0002061438DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback